ARQT is making big moves today. Find out why the stock is trading 5% higher:

Arcutis Biotherapeutics (ARQT) is trading 5% higher at $24.88 today. Shares of the stock are quickly outshining other names in the space on what is turning out to be a somewhat somber day for the Health Care sector.

While there was no immediate catalyst for the move, the stock has been having a strong month:

On Aug 10th they completed Enrollment in a Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis

On August 4th they announced that ZORYVE (roflumilast) cream 0.3% for topical use is now available in the United States for the treatment of plaque psoriasis. They also announced earnings where their EPS of -$1.31 beat by $0.12

Arcutis Biotherapeutics has been trading between a 52-week high of $26.14 and a 52-week low of $13.59. The stock has a market cap of $1.28 Billion.

Arcutis Biotherapeutics, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin.